Online Only Articles

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA
Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX, USA
Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, USA
Department of Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, USA
Department of Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Department of Hematology-Oncology, Baylor College of Medicine and Houston Methodist Hospital, TX, USA
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA
Vol. 103 No. 9 (2018): September, 2018 https://doi.org/10.3324/haematol.2018.187617